Fibrodysplasia Ossificans Progressiva: Clinical and Genetic Aspects

Orphanet Journal of Rare Diseases

Frederick S Kaplan¹  Eileen M Shore²  Robert J Pignolo¹ 

[1] Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104 USA;Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104 USA

关键词: Activin A receptor type I/Activin-like kinase 2 (ACVR1/ALK2);    toe malformation;    trauma;    progressive osseous heteroplasia;    heterotopic ossification;    myositis ossificans;    fibrodysplasia ossificans progressiva;   

Others  :  864487
DOI  :  10.1186/1750-1172-6-80

 received in 2011-03-10, accepted in 2011-12-01,  发布年份 2011

【 摘 要 】

Fibrodysplasia ossificans progressiva (FOP) is a severely disabling heritable disorder of connective tissue characterized by congenital malformations of the great toes and progressive heterotopic ossification that forms qualitatively normal bone in characteristic extraskeletal sites. The worldwide prevalence is approximately 1/2,000,000. There is no ethnic, racial, gender, or geographic predilection to FOP. Children who have FOP appear normal at birth except for congenital malformations of the great toes. During the first decade of life, sporadic episodes of painful soft tissue swellings (flare-ups) occur which are often precipitated by soft tissue injury, intramuscular injections, viral infection, muscular stretching, falls or fatigue. These flare-ups transform skeletal muscles, tendons, ligaments, fascia, and aponeuroses into heterotopic bone, rendering movement impossible. Patients with atypical forms of FOP have been described. They either present with the classic features of FOP plus one or more atypical features [FOP plus], or present with major variations in one or both of the two classic defining features of FOP [FOP variants]. Classic FOP is caused by a recurrent activating mutation (617G>A; R206H) in the gene ACVR1/ALK2 encoding Activin A receptor type I/Activin-like kinase 2, a bone morphogenetic protein (BMP) type I receptor. Atypical FOP patients also have heterozygous ACVR1 missense mutations in conserved amino acids. The diagnosis of FOP is made by clinical evaluation. Confirmatory genetic testing is available. Differential diagnosis includes progressive osseous heteroplasia, osteosarcoma, lymphedema, soft tissue sarcoma, desmoid tumors, aggressive juvenile fibromatosis, and non-hereditary (acquired) heterotopic ossification. Although most cases of FOP are sporadic (noninherited mutations), a small number of inherited FOP cases show germline transmission in an autosomal dominant pattern. At present, there is no definitive treatment, but a brief 4-day course of high-dose corticosteroids, started within the first 24 hours of a flare-up, may help reduce the intense inflammation and tissue edema seen in the early stages of the disease. Preventative management is based on prophylactic measures against falls, respiratory decline, and viral infections. The median lifespan is approximately 40 years of age. Most patients are wheelchair-bound by the end of the second decade of life and commonly die of complications of thoracic insufficiency syndrome.

【 授权许可】

   
2011 Pignolo et al; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]OMIM: Mendelian Inheritance in Man. [http://www.ncbi.nlm.nih.gov/omim] webcite
• [2]Shore EM, Feldman GJ, Xu M, Kaplan FS: The genetics of fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 2005, 3:201-204.
• [3]Rocke DM, Zasloff M, Peeper J, Cohen RB, Kaplan FS: Age-and joint-specific risk of initial heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. Clin Orthop Relat Res 1994, 243-248.
• [4]Kitterman JA, Kantanie S, Rocke DM, Kaplan FS: Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics 2005, 116:e654-e661.
• [5]Cohen RB, Hahn GV, Tabas JA, Peeper J, Levitz CL, Sando A, Sando N, Zasloff M, Kaplan FS: The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients. J Bone Joint Surg Am 1993, 75:215-219.
• [6]Kaplan FS, Glaser DL, Shore EM, Deirmengian GK, Gupta R, Delai P, Morhart P, Smith R, Le Merrer M, Rogers JG, Connor JM, Kitterman JA: The phenotype of fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 2005, 3:183188.
• [7]Pignolo RJ, Suda RK, Kaplan FS: The fibrodysplasia ossificans progressiva lesion. Clin Rev Bone Miner Metabol 2005, 3:195-200.
• [8]Schaffer AA, Kaplan FS, Tracy MR, O'Brien ML, Dormans JP, Shore EM, Harland RM, Kusumi K: Developmental anomalies of the cervical spine in patients with fibrodysplasia ossificans progressiva are distinctly different from those in patients with Klippel-Feil syndrome. Spine 2005, 30:1379-1385.
• [9]Kaplan FS, Strear CM, Zasloff MA: Radiographic and scintigraphic features of modeling and remodeling in the heterotopic skeleton of patients who have fibrodysplasia ossificans progressiva. Clin Orthop Relat Res 1994, 238-47.
• [10]Deirmengian GK, Hebela NM, O'Connell M, Glaser DL, Shore EM, Kaplan FS: Proximal tibial osteochondromas in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am 2008, 90:366-374.
• [11]Kaplan FS, Xu M, Seemann P, Connor M, Glaser DL, Carroll L, Delai P, Fastnacht-Urban E, Forman SJ, Gillessen-Kaesbach G, Hoover-Fong J, Köster B, Pauli RM, Reardon W, Zaidi S-A, Zasloff M, Morhart R, Mundlos S, Groppe J, Shore EM: Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat 2009, 30:379-90.
• [12]Kaplan FS, Glaser DL: Thoracic insufficiency syndrome in patients with fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 2005, 3:213-216.
• [13]Levy CE, Lash AT, Janoff HB, Kaplan FS: Conductive hearing loss in individuals with fibrodysplasia ossificans progressiva. Am J Audiol 1999, 8:29-33.
• [14]Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho T-J, Choi IH, Connor JM, Delai P, Glaser DL, Le Merrer M, Morhart R, Rogers JG, Smith R, Triffitt JT, Urtizberea JA, Zasloff M, Brown MA, Kaplan FS: A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nature Genetics 2006, 38:525-527.
• [15]Shen Q, Little SC, Xu M, Haupt J, Ast C, Katagiri T, Mundlos S, Seemann P, Kaplan FS, Mullins MC, Shore EM: The fibrodysplasia ossificans progressiva R20H ACVR1 mutation activates BMP independent chondrogenesis and zebrafish embargo ventralization. J Clin Invest 2009, 119:3462-3472.
• [16]Kaplan FS, Groppe J, Pignolo RJ, Shore EM: Morphogen receptor genes and metamorphogenes: skeleton keys to metamorphosis. Ann N Y Acad Sci 2007, 1116:113-33.
• [17]Kaplan FS, Shore EM, Gupta R, Billings PC, Glaser DL, Pignolo RJ, Graf D, Kamoun M: Immunological features of fibrodysplasia ossificans progressiva and the dysregulated BMP4 Pathway. Clin Rev Bone Miner Metab 2005, 3:189-193.
• [18]Kaplan FS, Xu M, Glaser DL, Collins F, Connor M, Kitterman J, Sillence D, Zackai E, Ravitsky V, Zasloff M, Ganguly A, Shore EM: Early diagnosis of fibrodysplasia ossificans progressiva. Pediatrics 2008, 121:e1295-e1300.
• [19]Adegbite NS, Xu M, Kaplan FS, Shore EM, Pignolo RJ: Diagnostic and mutational spectrum of progressive osseous heteroplasia (POH) and other forms of GNAS-based heterotopic ossification. Am J Med Genet A 2008, 146A:1788-96.
• [20]Pignolo RJ, Foley KL: Non-hereditary heterotopic ossification. Implications for injury, arthropathy, and aging. Clin Rev Bone Miner Metabol 2005, 3:261-266.
• [21]Nussbaum BL, Grunwald Z, Kaplan FS: Oral and dental healthcare and anesthesia for persons with fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 3:239-242.
• [22]International Fibrodysplasia Ossificans Progressiva Association [http://www.ifopa.org/en/living-with-fop-menu/treatment-guidelines.html] webcite
• [23]Kaplan FS, Zasloff MA, Kitterman JA, Shore EM, Hong CC, Rocke DM: Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am 2010, 92:686-691.